Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
24
Recruiting, any sponsor type, condition "generalized anxiety disorder"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed162
24 trials
Showing 1 to 24, recently updated first.
Tongji HospitalAcademic, hospital or other
NCT07944846 · 500 participants (planned) · Start Jun 18, 2026 · Primary completion Jun 30, 2027
Drug: Dexmedetomidine hydrochloride nasal spray · For: Preoperative Anxiety in Children
Sites: Wuhan, China
- A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety DisorderPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07759128 · 576 participants (planned) · Start Jul 28, 2026 · Primary completion Dec 6, 2028
Drug: SEP-363856 · For: Generalized Anxiety Disorder
Sites: Saraland, Alabama; Tucson, Arizona; Encino, California · 27 sites in all
- A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety DisorderPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07767903 · 384 participants (planned) · Start Aug 6, 2026 · Primary completion Oct 25, 2028
Drug: SEP-363856; Placebo · For: Generalized Anxiety Disorder
Sites: Phoenix, Arizona; Los Angeles, California; Redlands, California · 21 sites in all
- A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety DisorderPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07786454 · 1,120 participants (planned) · Start Oct 8, 2026 · Primary completion May 26, 2029
Drug: SEP-363856 · For: Generalized Anxiety Disorder
Sites: Jacksonville, Florida; Orlando, Florida; Jamaica, New York · 4 sites in all
- Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety DisorderPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06480383 · 705 participants (planned) · Start Aug 5, 2024 · Primary completion Mar 16, 2027
Drug: ITI-1284 10 mg; ITI-1284 20 mg and 1 more · For: Generalized Anxiety Disorder
Sites: Glendale, California; Imperial, California; Lemon Grove, California · 59 sites in all
- Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety DisorderPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06701903 · 570 participants (planned) · Start Nov 21, 2024 · Primary completion Oct 14, 2027
Drug: ITI-1284 10 mg; ITI-1284 20 mg and 1 more · For: Generalized Anxiety Disorder
Sites: Birmingham, Alabama; Little Rock, Arkansas; Rogers, Arkansas · 51 sites in all
- A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD TreatmentPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT07856420 · 705 participants (planned) · Start Sep 29, 2026 · Primary completion Sep 20, 2030
Drug: JNJ-99245354; Placebo · For: Generalized Anxiety Disorder
Sites: Temecula, California; Miami, Florida; Springfield, Massachusetts · 4 sites in all
- A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)Pivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT07807865 · 900 participants (planned) · Start Sep 3, 2026 · Primary completion Feb 18, 2030
Drug: ITI-1284 · For: Generalized Anxiety Disorder
Sites: Los Angeles, California; Miami, Florida; Brooklyn, New York
- Electroacupuncture for Generalized Anxiety Disorder: Clinical Efficacy and Neuroimaging MechanismsPivotal-lookingRecruiting
Lishu GaoAcademic, hospital or other
NCT07392645 · 123 participants (planned) · Start Mar 10, 2026 · Primary completion Oct 31, 2027
Drug: Medication · For: Generalized Anxiety Disorder
Sites: Hangzhou, China
- Cannabidiol-Assisted Learning for Managing Generalized Anxiety DisorderPivotal-lookingRecruiting
Wayne State UniversityAcademic, hospital or other
NCT07123467 · 90 participants (planned) · Start Nov 3, 2025 · Primary completion Aug 31, 2027
Drug: Low-Dose Cannabidiol; Placebo Matched to Moderate-Dose Cannabidiol and 2 more · For: Generalized Anxiety Disorder (GAD); Anxiety Disorders
Sites: Detroit, Michigan
- RE104 Safety and Efficacy Study in Generalized Anxiety DisorderPivotal-lookingRecruiting
Reunion Neuroscience IncIndustry
NCT07489651 · 160 participants (planned) · Start Apr 20, 2026 · Primary completion Jul 2027
Drug: RE104 for Injection; Placebo · For: Generalized Anxiety Disorder
Sites: Birmingham, Alabama; Gilbert, Arizona; Little Rock, Arkansas · 28 sites in all
Claudio N SoaresAcademic, hospital or other
NCT06969170 · 50 participants (planned) · Start May 16, 2025 · Primary completion Dec 31, 2027
Drug: Psilocybin (drug) · For: Generalized Anxiety Disorder (GAD)
Sites: Kingston, Canada
- Effect of Sedative and Anxiolytic Premedication on Children Experience After General AnesthesiaPivotal-lookingRecruiting
University Hospital, MontpellierAcademic, hospital or other
NCT05681572 · 1,000 participants (planned) · Start Apr 18, 2023 · Primary completion Oct 18, 2027
Drug: Midazolam; Dexmedetomidine and 1 more · For: Anesthesia
Sites: Montpellier, France
Synendos Therapeutics AGIndustry
NCT07478744 · 24 participants (planned) · Start Apr 22, 2026 · Primary completion Jan 2027
Drug: SYT-510; Placebo · For: Generalized Anxiety Disorder
Sites: London, United Kingdom
- Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety DisorderPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06846320 · 315 participants (planned) · Start Apr 29, 2025 · Primary completion Nov 2026
Drug: ABBV-932; Placebo for ABBV-932 and 1 more · For: Generalized Anxiety Disorder (GAD)
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 52 sites in all
- Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device in Adult Patients With Moderate to Severe Generalized Anxiety DisorderPivotal-lookingRecruiting
Psicofarma, S.A. De C.V.Industry
NCT07477990 · 162 participants (planned) · Start Mar 29, 2026 · Primary completion Jun 29, 2027
Drug: Pharmacological conventional treatment · For: General Anxiety Disorder
Sites: Mexico City, Mexico
GaizeIndustry
NCT07389473 · 50 participants (planned) · Start Apr 17, 2024 · Primary completion Dec 2027
Drug: Prescription Psychotropic Medications · For: ADHD; Depression Disorders; Mood Disorders and 2 more
Sites: Philadelphia, Pennsylvania
- Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety DisorderPivotal-lookingRecruiting
Anhui Medical UniversityAcademic, hospital or other
NCT07330648 · 216 participants (planned) · Start Oct 10, 2025 · Primary completion Jan 31, 2027
Drug: Crisugabalin 20mg bid; Venlafaxine-XR 75mg bid and 1 more · For: Generalized Anxiety Disorder
Sites: Hefei, China
- Comparing Two Doses of Oral Melatonin as Premedication in Children Undergoing SurgeryPivotal-lookingRecruiting
Al-Azhar UniversityAcademic, hospital or other
NCT06489327 · 120 participants (planned) · Start Jul 12, 2026 · Primary completion Dec 15, 2026
Drug: melatonin (Circadin ®) 0.2 mg/kg; melatonin (Circadin ®) 0.4 mg/kg and 1 more · For: Preoperative Anxiety
Sites: Cairo, Egypt; Madīnat Bābil, Iraq
Second Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06853431 · 80 participants (planned) · Start Mar 1, 2025 · Primary completion Nov 30, 2025
Drug: dexmedetomidine; Esketamine · For: Preoperative Anxiety; Preoperative Sedation; Children and 5 more
Sites: Wenzhou, China · 2 sites in all
Queen's UniversityAcademic, hospital or other
NCT06218030 · 10 participants (planned) · Start Oct 22, 2024 · Primary completion Apr 1, 2026
Drug: L-methylfolate · For: Generalized Anxiety Disorder
Sites: Kingston, Canada
- Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety DisorderPivotal-lookingRecruiting
Sichuan Jishengtang Pharmaceutical Co., Ltd.Industry
NCT05772104 · 495 participants (planned) · Start Apr 17, 2023 · Primary completion Feb 28, 2025
Drug: Shugan Jieyu Capsules; Shugan Jieyu Capsules Placebo · For: Generalized Anxiety Disorder
Sites: Beijing, China
- Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GADPivotal-lookingRecruiting
Beijing Union Pharmaceutical Factory LtdIndustry
NCT06243640 · 504 participants (planned) · Start Jul 25, 2023 · Primary completion Jun 30, 2026
Drug: Buagafuran capsules, 15mg/ capsule; Buagafuran capsules mimic, 0mg/ capsule · For: Generalized Anxiety Disorder
Sites: Beijing, China
- Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GADPivotal-lookingRecruiting
Beijing Union Pharmaceutical Factory LtdIndustry
NCT06243614 · 410 participants (planned) · Start Jul 24, 2023 · Primary completion Jun 30, 2026
Drug: Buagafuran capsules, 15mg/ capsule; Buspirone tablets, 5mg/ tablet and 2 more · For: Generalized Anxiety Disorder
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.